Common asthma drug helps fight hard-to-treat cancers, including aggressive breast cancers, early study finds
livescience - Scientists found that blocking a protein best known for its role in asthma enhances cancer immunotherapy in preclinical models.
AI Summary: Early studies report that a widely used asthma medication can switch off a tumor immune‑evasion pathway and restore anti‑tumor immunity in models and early human data, improving responses in some hard‑to‑treat cancers including aggressive breast tumours. Researchers call for larger trials to confirm clinical benefit and safety.
- Asthma drug revives anti‑tumor immunity in resistant cancers (5)
- Mechanisms and meetings on immunotherapy resistance (5)
- All Other Stories
Asthma drug revives anti‑tumor immunity in resistant cancers
Mechanisms and meetings on immunotherapy resistance
All Other Stories
FDA Approves AstraZeneca Drug With New Approach to Lowering High Blood Pressure
Frank Vinluan / medcitynews - AstraZeneca’s Baxfendy is the first FDA-approved drug in a new class of medicines called aldosterone synthase inhibitors. The new mechanism of action is important for patients and for AstraZeneca, which has been looking for new drugs with blockbuster pote…
AI Summary: The FDA has approved a first-in-class oral agent that uses a novel mechanism to lower resistant hypertension, offering an alternative for patients who haven’t responded to standard therapies. The move expands treatment options and signals renewed industry focus on innovative vascular targets — finally something for stubborn blood pressure to complain about.
Adding Retifanlimab To Chemotherapy Provides OS Benefit over Chemotherapy In First-Line Treatment of Patients with Advanced Squamous Anal Cancer
esmo - Findings from the final overall survival analysis in the POD1UM-303/InterAACT-2 study
AI Summary: A randomized first‑line trial found that adding retifanlimab to standard chemotherapy meaningfully improved overall survival for patients with advanced squamous anal cancer, signaling a new immunotherapy-containing option where few exist. The data from the POD1UM‑303/InterAACT‑2 program offer clinicians a viable strategy to extend life without reinventing the wheel.
Overactive MYC helps tumors fix DNA breaks and resist chemotherapy, study finds
medicalxpress - A protein best known for driving cancer growth also helps damaged tumor cells survive by repairing their DNA, according to a new study that could influence how some cancers are treated.
AI Summary: New research reveals overactive MYC drives tumor cells to repair DNA breaks more efficiently, enabling resistance to chemotherapy. By illuminating the repair pathways MYC hijacks, the study identifies potential targets to reverse resistance and improve treatment responses — because apparently cancers read the manual on how to survive your best shot.
- MYC hijacks DNA repair to enable chemo resistance (4)
- Other molecular drivers of chemoresistance and genome instability (3)
- Tumor cell death and immunity shape chemotherapy outcomes (3)
- All Other Stories
MYC hijacks DNA repair to enable chemo resistance
Other molecular drivers of chemoresistance and genome instability
Tumor cell death and immunity shape chemotherapy outcomes
All Other Stories
Data-Driven Decision Support in Obesity Management Commission: enabling more equitable and personalized obesity care
Paul W. Franks / nature - Nature Medicine, Published online: 12 May 2026; doi:10.1038/s41591-026-04363-0Announced in this Comment and in collaboration with Nature Medicine is the convening of the Data-Driven Decision Support in Obesity Management Commission, to promote adequate sc…
AI Summary: A phase 1/2 study of CRISPR‑Cas9 CD33‑deleted allogeneic hematopoietic cell transplantation followed by gemtuzumab ozogamicin maintenance reports encouraging early signals in AML. The gene‑editing approach aims to protect donor cells from CD33‑targeted therapy, potentially enabling safer post‑transplant maintenance and offering a novel strategy to marry cellular engineering with targeted antibody therapy.
- CD33‑targeted transplant and post‑transplant maintenance (4)
- Safety and ethical scrutiny of gene editing and gene therapy (3)
- Scaling cell therapy: accreditation and expanding CAR indications (3)
- All Other Stories
CD33‑targeted transplant and post‑transplant maintenance
Safety and ethical scrutiny of gene editing and gene therapy
Scaling cell therapy: accreditation and expanding CAR indications
All Other Stories
Historical DNA Links Colonial Graves to 1.3 Million Living Relatives and May Have Identified the Colony’s Second Governor
discovermagazine - Learn how researchers used DNA and 23andMe to connect 17th-century Maryland colonists to more than 1.3 million living people and potentially identify the colony’s second governor.
AI Summary: Ancient DNA from a colonial‑era burial site has been analyzed and linked to living descendants, potentially identifying one of the colony’s leaders. Among the finds is an 8‑year‑old African American boy buried with white colonists; researchers report his presence but cannot yet determine whether he was enslaved, prompting fresh questions about social status and burial practices.
Depressed mice successfully treated with smart contact lenses that zap their brains: New study
medicalxpress - Scientists in South Korea have developed experimental contact lenses designed to send electrical signals through the retina and into brain regions linked to mood. In mice, the technology appeared to improve depression-like behavior.
AI Summary: Preclinical studies report smart contact lenses that deliver tiny electrical signals can reduce depressive-like behaviors in mice, matching effects seen with standard antidepressants. Researchers caution the work is early — promising biologically, but still a long way from fashionable therapeutic eyewear for humans — and will require safety, dosing and translational studies before any clinic-ready hype.
Omid Veiseh: First-in-Human Clinical Trial of IL-2 Cytokine Factories in Refractory Ovarian Cancer
oncodaily - Omid Veiseh, Professor and CPRIT Scholar in Cancer Research at Rice University and Co-Founder and Managing Partner of RBL LLC, shared a post on LinkedIn: “Excited to publish the results […]
AI Summary: A first‑in‑human trial of implantable IL‑2 “cytokine factories” in refractory ovarian cancer reported encouraging early safety and biological activity, offering a localized immune‑stimulation strategy that may boost tumor responses while avoiding systemic toxicity. Investigators described the device‑based platform as a potential option for patients with limited alternatives, pending larger efficacy studies.
Antiviral ensitrelvir cuts risk of COVID-19 in household contacts by two-thirds, study finds
medicalxpress - The antiviral drug ensitrelvir prevents infection in household contacts of COVID-19 patients when given within 72 hours after symptom onset in the index patient, according to a Phase III randomized controlled trial published in the New England Journal of …
AI Summary: A randomized trial shows the oral antiviral ensitrelvir, used as post‑exposure prophylaxis, reduced the risk of symptomatic COVID‑19 in household contacts by roughly two‑thirds. The finding suggests a practical option for preventing spread after close exposure, offering public‑health teams a less dramatic but highly useful tool than lockdowns.
BeOne’s next-gen BCL2 inhibitor wins FDA approval, taking aim at Venclexta
Ayisha Sharma / endpoints - BeOne Medicines has clinched US accelerated approval for its drug sonrotoclax in a rare but aggressive form of blood cancer, where AbbVie and Genentech’s Venclexta is used off-label. The FDA greenlit ...
AI Summary: BeOne Medicines secured FDA approval for a next-generation BCL2 inhibitor, positioning the drug as a direct challenge to AbbVie/Roche’s Venclexta franchise. The move reshuffles competitive dynamics in hematology, potentially offering clinicians an alternative and setting the stage for market share battles and payer negotiations. Expect aggressive positioning and head-to-head data requests.
Positive VOLGA Phase III Results for Imfinzi Plus Neoadjuvant EV in MIBC
oncodaily - On May 14, 2026, AstraZeneca announced positive high-level results from a planned interim analysis of the Phase III VOLGA trial, evaluating perioperative Imfinzi with or without Imjudo in combination with […]
AI Summary: Phase III VOLGA trial results reveal that combining durvalumab (Imfinzi) with neoadjuvant enfortumab vedotin improved survival outcomes in muscle‑invasive bladder cancer. Investigators and industry voices highlight potential practice-changing implications for perioperative therapy, while stakeholders weigh regulatory filings and integration into treatment guidelines. Clinicians will want full datasets and toxicity details.
- Clinician reactions, biology and resistance concerns (4)
- Global GU oncology meetings and community coverage (3)
- VOLGA Phase III readout and regulatory landscape (3)
- All Other Stories
Clinician reactions, biology and resistance concerns
Global GU oncology meetings and community coverage
VOLGA Phase III readout and regulatory landscape
All Other Stories
Favipiravir for Lassa fever: an open-label, randomized controlled phase 2 trial
Cyril Erameh / nature - Nature Medicine, Published online: 15 May 2026; doi:10.1038/s41591-026-04402-wAn open-label, randomized controlled phase 2 trial comparing favipiravir with ribavirin for the treatment of mild-to-moderate Lassa fever in Nigeria found that favipiravir was s…
AI Summary: An open-label, randomized Phase 2 trial of favipiravir for Lassa fever reported encouraging results, suggesting antiviral benefit where few options exist. The study offers early clinical proof-of-concept, especially important for endemic West African settings, and calls for larger trials to confirm efficacy, optimize dosing, and assess deployment logistics.
Bristol Myers Squibb and Hengrui Forge $15.2 Billion Strategic Alliance, Reshaping China-Out Licensing Landscape
oncodaily - Bristol Myers Squibb (NYSE: BMY) and Jiangsu Hengrui Pharma (600276.SH; 01276.HK) on Tuesday unveiled one of the largest cross-border biopharma collaborations of the year: a global strategic alliance encompassing 13 […]
AI Summary: Bristol Myers Squibb and Hengrui Pharma announced a sweeping strategic alliance covering multiple oncology assets, with potential payments and milestones that could reach roughly $15.2 billion. The deal bundles discovery, development and commercialization rights, reshaping China‑out‑licensing dynamics and signaling continued consolidation and collaboration in global cancer drug development.
Personalized Brain Cancer Vaccine May Help Against Aggressive Glioblastoma
discovermagazine - Discover how a personalized DNA vaccine trained patients’ immune systems to target their own tumors, with one participant remaining cancer-free nearly five years later.
AI Summary: A customized vaccine targeting each patient's tumor has demonstrated encouraging immune responses and signs of clinical benefit against aggressive glioblastoma. Researchers report enhanced T‑cell activity and preliminary survival signals, suggesting personalized neoantigen vaccines may help control this stubborn brain cancer and warrant larger, controlled trials to confirm impact.
- New models and datasets speeding brain tumor research (3)
- Next-gen glioblastoma immunotherapies: CAR T, drugs, stem cells (3)
- Personalized glioblastoma vaccine: early immune and survival signals (3)
- All Other Stories
New models and datasets speeding brain tumor research
Next-gen glioblastoma immunotherapies: CAR T, drugs, stem cells
Personalized glioblastoma vaccine: early immune and survival signals
All Other Stories
A Cancer Driven by Ultra-Rare Mutation Gets Its First FDA-Approved Therapy
Frank Vinluan / medcitynews - Partner Therapeutics’ Bizengri is now FDA approved for treating advanced cases of cholangiocarcinoma driven by NRG1 gene fusions. Partner acquired U.S. rights to this bispecific antibody from Merus in 2024. The post A Cancer Driven by Ultra-Rare Mutation …
AI Summary: The FDA approved zenocutuzumab‑zbco for NRG1‑fusion–positive cholangiocarcinoma, delivering the first cleared therapy for cancers driven by this ultra‑rare genomic alteration. Trial data showed meaningful responses in heavily pretreated patients, prompting regulators to greenlight a precision option that offers targeted benefit where none existed — a small‑population win for genomic oncology.
Study reveals how parenting styles shape babies' willingness to help others
medicalxpress - New research from Durham University shows that the way parents instruct and encourage infants to help plays a key role in how helping behavior develops, and that these approaches vary across cultures.
AI Summary: The RESET‑C trial tested one preoperative dose of pembrolizumab in localized mismatch repair‑deficient colon cancer and recorded unexpectedly high tumor responses, with several patients remaining cancer‑free for nearly three years. The dramatic neoadjuvant activity suggests immune priming could reshape perioperative strategies and raises questions about surgery timing and organ preservation.
UCB bets $2 billion on Candid's T cell engager ambitions
Kyle LaHucik / endpoints - Ken Song has done it again. The biopharma veteran's all-out effort to prove T cell engagers' potential in autoimmune diseases is getting picked up by one of Europe’s oldest pharma companies. UCB is paying $2 ...
AI Summary: UCB has struck a roughly $2 billion deal to acquire Candid, betting heavily on Candid’s T‑cell engager platform to reset immune‑based oncology programs. The acquisition boosts UCB’s immuno‑oncology pipeline and signals intensified competition in T‑cell engager development, with investors and researchers watching closely to see how science translates into clinical wins.
The peptide problem: Hype is outrunning the evidence
medicalxpress - Health Canada recently warned Canadians not to buy or inject unauthorized peptide drugs sold online, naming products that include BPC-157, CJC-1295, ipamorelin, TB-500 and retatrutide.
AI Summary: The booming market for peptide therapies and supplements is racing past the science. Researchers report limited clinical evidence, unclear long-term safety, and weak regulatory oversight, while consumer demand and marketing hype surge. Clinicians urge caution: biological plausibility isn’t the same as proven benefit, and enthusiasm should not substitute for rigorous trials.
Atara, Pierre Fabre's cell therapy to get another shot at FDA approval
Max Gelman / endpoints - There's new life for a twice-rejected T cell therapy from Atara Biotherapeutics and Pierre Fabre Pharmaceuticals. US regulators are willing to reconsider using a Phase 3 study as the basis for an approval, Atara said ...
AI Summary: Regulators have agreed to re-examine a previously rejected cell‑therapy application for a rare lymphoma, giving the Atara‑Pierre Fabre program another opportunity at approval. The decision follows additional data and stakeholder engagement, offering the developer a second bite at the apple and patients a renewed, if cautious, hope for a novel treatment pathway.
FDA approves blood test to guide breast cancer therapy
Ella Jeffries / beckershospitalreview - The FDA has approved a companion diagnostic from Guardant Health to identify patients eligible for treatment with a targeted therapy developed by Pfizer and Arvinas. The blood-based test detects ESR1 mutations in patients with estrogen receptor-positive, …
AI Summary: The FDA approved a blood‑based test to help guide breast cancer treatment selection, authorizing a diagnostic that identifies patients more likely to benefit from specific therapies. The move could reduce unnecessary treatments and sharpen precision oncology, though broad clinical adoption will depend on further validation, payer coverage and clinician trust.
- ESMO Breast highlights and expert commentary (4)
- FDA clearances reshape diagnostics and therapies (3)
- Liquid biopsy, mutations and treatment resistance (4)
- All Other Stories